US Patent Issued to ImmunityBio on July 14 for "Compositions and methods for NK-92 cells expressing native CD16" (California Inventors)

ALEXANDRIA, Va., July 14 -- United States Patent no. 12,681,020, issued on July 14, was assigned to ImmunityBio Inc. (San Diego).

"Compositions and methods for NK-92 cells expressing native CD16" was invented by Barry J. Simon (San Diego), Laurent H. Boissel (San Diego) and Prachi Jain (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "A recombinant NK-92 cell has a constitutive active promotor that effects expression of native CD16, and most preferably homogenous CD16 158V. Further contemplated recombinant NK-92 cells also include a recombinant nucleic acid that encodes an intracellularly retained interleukin (e.g., IL-2 or er-IL-2), wherein the recombinant NK-92 cell will secrete no more than 5,000 ...